NEC / NEC OncoImmunity — neoantigen vaccine coverage

Clinical

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

NEC Bio B.V. is conducting a Phase I/II multicenter trial of NECVAX-NEO1 combined with PD-1/PD-L1 monoclonal antibodies in solid tumors. The study stratifies patients by response to prior checkpoint inhibitor therapy (Stable Disease/Partial Response vs. Progressive Disease), testing the vaccine's ability to rescue or sustain response in advanced settings.

clinicaltrials · brief 2026-06-04 · published 2026-01-08

Clinical

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

NEC Bio B.V. is recruiting for a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine, in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine in combination with standard-of-care anti-PD-1 therapy and chemotherapy, with potential post-surgical extension.

clinicaltrials · brief 2026-05-29 · published 2026-05-26